Welcome to the RfB

This website provides all information concerning the accredited EQA schemes of the RfB:

News

New Survey: Neurofilament Light Chain (NfL) in Serum

The RfB is expanding its survey program to include the determination of neurofilament light chain (NfL) in serum. This measurement serves as a biomarker for assessing neuroaxonal damage, particularly in multiple sclerosis. Scheduled dates for 2025 are planned for June and November.
New Survey: Preeclampsia Markers (PM)

The RfB is expanding its external quality assurance services and will offer the survey for preeclampsia markers twice a year starting in 2025. Participants can determine analytes such as PlGF, sFLT-1, and the PlGF/sFLT-1 ratio. Registration is done through the participant account.
The guideline Rili-BÄK is now available in English!

The Rili-BÄK is now available in the official translation of the German medical association.
IgG subclass determination in IG4/24

Starting with the survey IG4/24 you have the possibility to perform the IgG subclass determination (IgG1, IgG2, IgG3, IgG4).
EurA1cTrial 2022

EurA1c, the trial exploring the effectiveness of HbA1c tests across various countries and manufacturers, was conducted for the seventh time in 2022. Over 4,000 laboratories in 22 countries participated. The report is now available on our website.

Office
Friesdorfer Straße 153
53175 Bonn

Phone: +49 2 28 / 92 68 95 - 0
Fax: +49 2 28 / 92 68 95 - 29

Internet: www.rfb.bio
E-mail: info@spmd-rfb.de

Download:
certificate of accreditation